Greens welcome AstraZeneca approval but say further diversity is needed.

The Greens welcome the news that AstraZeneca has been provisionally approved by the Therapeutic Goods Administration for use in Australia.
“However we cannot put all our eggs in one basket. It’s clear with differing rates of efficacy and with new Covid-19 strains developing that we must continue to expand and diversify Australia’s vaccine portfolio”, Australian Greens spokesperson on Health Senator Rachel Siewert said.
“Australia needs to build a diverse portfolio to rapidly pivot to deal with new strains and to develop herd immunity, including securing deals with Moderna and more Pfizer doses.
“We should also be investing in the development of Australia’s capacity to locally manufacture vaccines and medicines that use mRNA technology. This would allow us to produce mRNA vaccines like Pfizer onshore in a publicly owned facility.
“We need to ramp up CSL’s capacity to start locally producing Novavax at the same time as AstraZeneca given the promising Phase 3 Trial data.
“It is essential that Australia supports our neighbours in the pacific region to receive timely and adequate access to Covid-19 vaccines. No one is safe until all of us are safe.”